Cord blood ex vivo expansion — the cytokine-driven, small molecule-enhanced, and stromal co-culture systems increasing CD34+ cell numbers 10-100 fold to overcome the cell dose limitation representing the most critical manufacturing innovation — creates the most commercially dynamic market segment, with the Stem Cell Umbilical Cord Blood Market reflecting expansion technology as the...